AR104257A1 - Tableta de ribociclib - Google Patents

Tableta de ribociclib

Info

Publication number
AR104257A1
AR104257A1 ARP160101012A ARP160101012A AR104257A1 AR 104257 A1 AR104257 A1 AR 104257A1 AR P160101012 A ARP160101012 A AR P160101012A AR P160101012 A ARP160101012 A AR P160101012A AR 104257 A1 AR104257 A1 AR 104257A1
Authority
AR
Argentina
Prior art keywords
ribociclib
tablet
pharmaceutical tablet
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP160101012A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR104257A1 publication Critical patent/AR104257A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un comprimido farmacéutico oral que comprende ribociclib o su sal farmacéuticamente aceptable. Reivindicación 2: El comprimido de la reivindicación 1 que comprende succinato de ribociclib. Reivindicación 14: Un comprimido farmacéutico oral recubierto que comprendo ribociclib o su sal farmacéuticamente aceptable en donde el revestimiento comprende polivinil alcohol (PVA). Reivindicación 15: Un comprimido farmacéutico oral recubierto que comprende succinato de ribociclib en el que el recubrimiento comprende PVA.
ARP160101012A 2015-04-16 2016-04-14 Tableta de ribociclib AR104257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
AR104257A1 true AR104257A1 (es) 2017-07-05

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101012A AR104257A1 (es) 2015-04-16 2016-04-14 Tableta de ribociclib

Country Status (29)

Country Link
US (3) US10799506B2 (es)
EP (2) EP4197530A1 (es)
JP (1) JP2018514523A (es)
KR (1) KR20170137101A (es)
CN (2) CN107530292B (es)
AR (1) AR104257A1 (es)
AU (4) AU2016248017A1 (es)
BR (1) BR112017021283A2 (es)
CA (1) CA2982425C (es)
CL (1) CL2017002593A1 (es)
CO (1) CO2017010510A2 (es)
DK (1) DK3283058T3 (es)
EA (1) EA201792290A1 (es)
EC (1) ECSP17075052A (es)
ES (1) ES2938261T3 (es)
FI (1) FI3283058T3 (es)
HR (1) HRP20230053T1 (es)
HU (1) HUE061213T2 (es)
IL (1) IL254818A0 (es)
MX (1) MX2017013350A (es)
PE (1) PE20180035A1 (es)
PH (1) PH12017501820A1 (es)
PL (1) PL3283058T3 (es)
PT (1) PT3283058T (es)
SG (1) SG11201708084PA (es)
SI (1) SI3283058T1 (es)
TN (1) TN2017000422A1 (es)
TW (1) TW201642864A (es)
WO (1) WO2016166703A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017021283A2 (pt) 2015-04-16 2018-06-26 Novartis Ag comprimido de ribociclib
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
AU2020405427A1 (en) 2019-12-16 2022-07-14 Lunella Biotech, Inc. Selective CDK4/6 inhibitor cancer therapeutics
KR20220113986A (ko) 2019-12-16 2022-08-17 루넬라 바이오테크 인코포레이티드 선택적 cdk 4/6 억제제 암 치료제
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
TW202329977A (zh) 2022-01-25 2023-08-01 瑞士商諾華公司 瑞博西尼藥物組成物
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3672314B2 (ja) * 1994-07-12 2005-07-20 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド 防湿性フィルム被覆材組成物、方法および被覆成形物
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
HUE031633T2 (en) * 2011-02-11 2017-07-28 Wista Lab Ltd Phenothiazine diaminium salts and their use
KR102238970B1 (ko) * 2012-07-13 2021-04-09 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
EP3251673A1 (en) * 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
CN105209073A (zh) * 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
BR112017021283A2 (pt) 2015-04-16 2018-06-26 Novartis Ag comprimido de ribociclib
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
SG11201708084PA (en) 2017-10-30
IL254818A0 (en) 2017-12-31
FI3283058T3 (fi) 2023-03-01
PH12017501820A1 (en) 2018-04-23
US20230104792A1 (en) 2023-04-06
HUE061213T2 (hu) 2023-05-28
MX2017013350A (es) 2018-01-25
EP4197530A1 (en) 2023-06-21
US20200390771A1 (en) 2020-12-17
AU2019201929B2 (en) 2020-07-09
KR20170137101A (ko) 2017-12-12
CN115554257A (zh) 2023-01-03
EA201792290A1 (ru) 2018-02-28
ES2938261T3 (es) 2023-04-05
JP2018514523A (ja) 2018-06-07
CO2017010510A2 (es) 2018-03-20
AU2020250190A1 (en) 2020-11-05
TN2017000422A1 (en) 2019-01-16
SI3283058T1 (sl) 2023-03-31
CN107530292B (zh) 2022-11-01
TW201642864A (zh) 2016-12-16
CN107530292A (zh) 2018-01-02
ECSP17075052A (es) 2018-02-28
EP3283058B1 (en) 2022-11-16
BR112017021283A2 (pt) 2018-06-26
AU2019201929A1 (en) 2019-04-11
AU2016248017A1 (en) 2017-10-19
DK3283058T3 (da) 2023-02-13
AU2022215155A1 (en) 2022-09-01
PE20180035A1 (es) 2018-01-09
EP3283058A1 (en) 2018-02-21
WO2016166703A1 (en) 2016-10-20
CL2017002593A1 (es) 2018-05-18
PL3283058T3 (pl) 2023-03-20
US10799506B2 (en) 2020-10-13
US20180071292A1 (en) 2018-03-15
HRP20230053T1 (hr) 2023-03-03
PT3283058T (pt) 2023-02-03
CA2982425C (en) 2023-10-31
CA2982425A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
AR104257A1 (es) Tableta de ribociclib
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
UY36275A (es) Compuestos aminopirimidinilo
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
NI201900052A (es) Formulaciones farmacéuticas
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
EP3556758A4 (en) INHIBITOR OF CDK4 / 6
PH12016500626B1 (en) Film coated tablet containing choline alfoscerate and process for preparing the same
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
UY37941A (es) Derivados de bencimidazol y sus usos
EP3106152A4 (en) Orally disintegrating tablet coated with film
EP3756639A4 (en) TABLET CASSETTE
EP3694522A4 (en) TWO-LAYER PHARMACEUTICAL TABLET FORMULATION
UY35000A (es) ?formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa?.
EP3831373A4 (en) SOLID DRUG FORMULATION CONTAINING A STABILIZER
EP3603641A4 (en) PHARMACEUTICAL COMPOSITION WITH A DUSP1 INHIBITOR
EP3697393A4 (en) PHARMACEUTICAL DOSAGE FORMS
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
ITUA20163606A1 (it) Sistema ottico per la enfatizzazione 3d di effetti luminosi.
EA201891885A1 (ru) Содержащая прегабалин высоконабухаемая трехслойная таблетка с замедленным высвобождением для перорального приема
EP3848050A4 (en) PHARMACEUTICALS WITH HSP47 INHIBITOR TO INCREASE SENSITIVITY TO CHEMOTHERAPEUTICS
EP3675842A4 (en) PHARMACEUTICAL DOSAGE FORMS
EP3883561A4 (en) PHARMACEUTICAL PROCESSES
IL261618A (en) Dosage unit for immediate release of ghb or one of its medically acceptable salts, given orally and used to maintain abstinence from alcohol

Legal Events

Date Code Title Description
FB Suspension of granting procedure